Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Bio-Techne are incentivised to make money from our test anyhow once it gets going.
It's then the portfolio after that in research...
I'd hope that if anyone approaches, we say no to offers in pennies.
Potential revenues for NY and Cali for example who are legislating testing/screening alone would be big. In bio buyouts for firms with revs is not the usual annual cost but a look at projections for ten years.
So then it's all the other US states, insurance, and here in the UK with the NHS and still so far no reason to suspect China won't go ahead too.
We all have our own targets, yes mine is enormous but I've been here for so long I'll happily hold.
Exosomes can be used to carry cellular messages or even corrective expressions to communicate with certain cells or expressions.
In short, exosome therapy can be used to help the body remember how to fight cancer. For most cancers, we get disease because the body forgets how to recognise it as a foreign protein.
Is mental.
How and why the market isn't picking it up I'll never know.
You won't be able to buy in volume on markers. Many of us sat on millions now.
It's when and not if...
Too many sat waiting for their favourite pump and dump crews to mention it to them too... Research for yourselves. That's how YOU make money and not the ramp crew.
Earl, please stop spamming. Love the enthusiasm but there are many great posts being pushed away with the ramp.
I'd also suggest people look at the longer term potential as opposed to a short term buyout.
If you are in this, you want the company to realise a good amount of it's potential before it is even considered. This way you are talking billions in mcap and pounds in share price. Not pennies.
This is typically where the punters from aim get things wrong.
The idea is to take away the need for invasive processes.
CT isn't the most accurate form of screening. So with a blood test diagnostic, the idea is to ascertain if there is a greater chance of someone having cancer and then being prioritised accordingly.
Remember, they aren't investors or groups with a legitimate hold or position. They hold a position on something that is yet to exist.
So it's the reverse of how a normal position would work. If it was legitimate they'd have to rebuy lower than the current price. They don't. They only have to rebuy below where the next allotments take place to make on it.
It's not the facility that matters. We know the price of that.
It's my view of what they'd do to the shares that are currently made of thin air. As it's under 2.1p they can print a "buy" at any price between here and that to reconcile the book and pocket the difference between what they "sold" at and the 2.1p.
They only start to lose if they have to print a buy over 2.1p.